Search

Your search keyword '"Aurélie Du Thanh"' showing total 19 results
Start Over Author "Aurélie Du Thanh" Publisher hal ccsd
19 results on '"Aurélie Du Thanh"'

1. Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs

Author

Laurence Bouillet, Olivier Fain, Guillaume Armengol, Magali Aubineau, Claire Blanchard-Delaunay, Marie-Caroline Dalmas, Claire De Moreuil, Aurélie Du Thanh, Delphine Gobert, Stéphane Guez, Cyrille Hoarau, Roland Jaussaud, Pierre-Yves Jeandel, Hervé Maillard, Nicolas Marmion, Agathe Masseau, Céline Menetrey, Yann Ollivier, Fabien Pelletier, Geneviève Plu-Bureau, Laurent Sailler, Denis Vincent, Benoit Bouquillon, Edouard Verdier, Pierre Clerson, Isabelle Boccon-Gibod, David Launay, Centre Hospitalier Universitaire [Grenoble] (CHU), Centre de référence national des angiœdèmes (CREAK), CHU Grenoble-Université Grenoble Alpes (UGA), Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 (TIMC ), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Rouen, Normandie Université (NU), Hospices Civils de Lyon (HCL), Centre Hospitalier Georges Renon [Niort] (CH Georges Renon Niort), CHU Strasbourg, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier]-Université de Montpellier (UM), Université de Montpellier (UM), CHU de Bordeaux Pellegrin [Bordeaux], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Le Mans (CH Le Mans), CHU Sud Saint Pierre [Ile de la Réunion], Centre hospitalier universitaire de Nantes (CHU Nantes), CH Esquirol [Limoges] (CH Esquirol), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Maternité Port-Royal [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Equipe 1 : EPOPé - Épidémiologie Obstétricale, Périnatale et Pédiatrique (CRESS - U1153), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Soladis, Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
Pulmonary and Respiratory Medicine, Quality of life, MESH: Complement C1 Inhibitor Protein, MESH: Quality of life, Administration route, MESH: Angioedemas, Hereditary, Unmet needs, Immunology and Allergy, Humans, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Side effects, Survey, Hereditary angioedema, MESH: Humans, Angioedemas, Hereditary, General Medicine, MESH: Tranexamic Acid, Treatment, Long-term prophylaxis, Tranexamic Acid, Expert opinion, Androgens, MESH: Androgens, MESH: Progestins, Progestins, Complement C1 Inhibitor Protein, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Decision-making
Abstract

Background: Hereditary angioedema (HAE) is characterized by unpredictable and potentially life-threatening attacks of cutaneous and submucosal swelling. Over the past decade, new agents, based on a better understanding of the underlying biologic mechanisms of HAE, have changed the face of long-term prophylaxis (LTP). Objective: The objective was to describe current practices and unmet needs with regard to LTP for HAE in expert centers in France. Methods: The study was conducted in France in 2020. Based on their experience with patients with HAE who had visited their center at least once in the past 3 years, physicians from 25 centers who are expert in the management of HAE were requested to fill in a questionnaire that encapsulated their active patient list, criteria for prescribing LTP, and medications used. They were asked about potential unmet needs with currently available therapies. They were asked to express their expectations with regard to the future of HAE management. Results: Analysis was restricted to 20 centers that had an active patient file and agreed to participate. There were 714 patients with C1 inhibitor (C1-INH) deficiency, of whom 423 (59.2%) were treated with LTP. Altered quality of life triggered the decision to start LTP, as did the frequency and severity of attacks. Ongoing LTP included androgens (28.4%), progestins (25.8%), lanadelumab (25.3%), tranexamic acid (14.2%), intravenous C1-INHs (5.6%), and recombinant C1-INH (0.7%). Twenty-nine percent of the patents with LTP were considered to still have unmet needs. Physicians' concerns varied among therapies: poor tolerability for androgens and progestins, a lack of efficacy for tranexamic acid and progestins, dosage form, and high costs for C1-INHs and lanadelumab. Physicians' expectations encompassed more-efficacious and better-tolerated medications, easier treatment administration for the sake of improved quality of life of patients, and less-expensive therapies. Conclusion: Despite the recent enrichment of the therapeutic armamentarium for LTP, physicians still expressed unmet needs with currently available therapies.

Published
2022
Full Text
View/download PDF

2. Stratégie d’espacement des doses de dupilumab dans la dermatite atopique de l’adulte en vie réelle : résultats d’une étude multicentrique française

Author

Catherine Droitcourt, Audrey Nosbaum, Angèle Soria, Fatma Jendoubi, Aurélie Du-Thanh, Sébastien Barbarot, Florence Tetart, Marie Tauber, Jason Shourik, Julien Seneschal, Carle Paul, Claire Bernier, J.-D. Bouaziz, Aude Clement, Nadia Raison-Peyron, Marie Jachiet, Valois Aude, Françoise Giordano-Labadie, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-André, Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Service de Dermatologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier], Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de pneumologie, allergologie, mucoviscidose pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Faculté de Médecine - Clermont-Auvergne (FM - UCA), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service d'allergologie et immunologie clinique, Centre hospitalier Lyon Sud, Hospices civils de Lyon, Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Dermatite atopique, [SDV]Life Sciences [q-bio], Ocean Engineering, Dupilumab, Safety, Risk, Reliability and Quality
Abstract

International audience

Published
2021
Full Text
View/download PDF

3. Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis

Author

Alexandre Thibault Jacques Maria, Cyrille Coustal, Eric Assenat, Aurélie Du Thanh, François Roubille, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Saint Eloi (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), MORNET, Dominique, CHU Saint-Eloi, and Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
0303 health sciences, Cancer Research, Durvalumab, business.industry, Immune checkpoint inhibitors, [SDV]Life Sciences [q-bio], Cutaneous toxicity, Dermatomyositis, medicine.disease, Myasthenia gravis, 3. Good health, [SDV] Life Sciences [q-bio], 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Cancer research, business, ComputingMilieux_MISCELLANEOUS, 030304 developmental biology
Abstract

International audience

Published
2021
Full Text
View/download PDF

4. Angiœdèmes par déficit acquis en C1-inhibiteur : recommandations du CREAK pour le diagnostic et la prise en charge

Author

Gaëlle Hardy, Virginie Panayotopoulos, F. Defendi, D. Launay, Aurélie Du-Thanh, Laurence Bouillet, G. Armengol, D. Gobert, Isabelle Boccon-Gibod, Pierre-Yves Jeandel, Nicolas Javaud, Olivier Fain, Fabien Pelletier, Paul Coppo, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence national des angiœdèmes (CREAK), CHU Grenoble-Université Grenoble Alpes (UGA), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Rouen, Normandie Université (NU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nice (CHU Nice), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Lille, and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
medicine.medical_specialty, Bradykinine, [SDV]Life Sciences [q-bio], Bradykinin, C1-inhibitor, 030204 cardiovascular system & hematology, Angiœdème acquis, Thrombophilia, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, immune system diseases, Icatibant, C1-inhibiteur, Internal Medicine, medicine, Déficit acquis en C1-inhibiteur, 030212 general & internal medicine, Danazol, Angioedema, Angiœdème bradykinique, business.industry, Acquired C1-inhibitor deficiency, Gastroenterology, Kallikrein, medicine.disease, Dermatology, 3. Good health, chemistry, Rituximab, medicine.symptom, business, Tranexamic acid, Bradykininin angioedema, medicine.drug
Abstract

International audience; Acquired angioedema with C1-inhibitor deficiency is a rare and peculiar entity belonging to the spectrum of bradykinin angioedemas. It usually occurs in subjects over 60 years old, and is mostly associated with a B-cell lymphoid hemopathy or a monoclonal gammopathy.The diagnosis relies on at least one angioedema episode, lasting more than 24 h, and on the decrease of functional C1-inhibitor. Low C1q is observed in 90% of patients, and an anti C1-inhibitor antibody is found in 50% of patients.The treatment of severe attacks relies on icatibant or C1-inhibitor perfusions. Long term prophylaxis in patients with frequent attacks requires treatment of the associated hemopathy if so. In case of idiopathic angioedema, tranexamic acid and danazol may be used, provided that there is-no thrombophilia; as well as rituximab as second-line treatment. Inhibitors of kallikrein still need to be evaluated in this therapeutic indication.; Les angiœdèmes par déficit acquis en C1-inhibiteur représentent une entité rare au sein des angiœdèmes bradykiniques. Ils diffèrent des formes héréditaires essentiellement par le terrain, car ils surviennent chez des sujets âgés de 60 ans en moyenne, et sont, le plus souvent, associés à une hémopathie lymphoïde B de bas grade ou à une gammapathie monoclonale.Leur diagnostic repose sur la survenue d'au moins un épisode d'angiœdème durant plus de 24 heures et sur la diminution de C1-inhibiteur fonctionnel. Une baisse du C1q est présente dans 90 % des cas et un anticorps anti C1-inhibiteur chez 50 % des patients.Le traitement des crises sévères repose sur l'icatibant ou l'administration de C1-inhibiteur. Le traitement préventif, indiqué en cas de crises fréquentes, nécessite le traitement de l'hémopathie identifiée. En l'absence de pathologie associée, l'acide tranexamique ou le danazol sont des options à envisager en l'absence de facteur de risque de thrombose, et le rituximab peut être proposé en cas d'échec. La place des inhibiteurs de la kallicréine sera à définir dans cette indication.

Published
2020
Full Text
View/download PDF

5. Hemophagocytic lymphohistiocytosis in advanced melanoma treated with dabrafenib and trametinib combination: two cases

Author

Quentin Samaran, Olivier Dereure, Sarah Theret, O. Becquart, C. Lesage, Aurélie Du Thanh, Dorian Belakebi, Céline Girard, Bernard Guillot, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Targeted therapy, 0302 clinical medicine, Oximes, Melanoma, Trametinib, MESH: Aged, MESH: Middle Aged, Imidazoles, Middle Aged, MESH: Oximes, 3. Good health, 030220 oncology & carcinogenesis, MESH: Imidazoles, medicine.drug, medicine.medical_specialty, Combination therapy, Pyridones, MESH: Melanoma, MESH: Pyrimidinones, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, Pyrimidinones, Lymphohistiocytosis, Hemophagocytic, 03 medical and health sciences, Internal medicine, MESH: Pyridones, MESH: Lymphohistiocytosis, Hemophagocytic, medicine, Humans, Aged, Hemophagocytic lymphohistiocytosis, Cytopenia, MESH: Humans, business.industry, MESH: Skin Neoplasms, Dabrafenib, Immunotherapy, medicine.disease, MESH: Male, 030104 developmental biology, Concomitant, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; Hemophagocytic lymphohistiocytosis (HLH) has been only rarely reported in patients with BRAF-mutated advanced melanoma treated with targeted therapies and never with first-line dabrafenib/trametinib combination thus far. Two patients treated with first-line dabrafenib and trametinib combination therapy for metastatic melanoma presented with sudden occurrence of fever, cytopenia, rhabdomyolysis, hepatic cytolysis, hypertriglyceridemia and very high ferritin levels after few weeks of treatment, associated with concomitant epstein-barr virus (EBV) reactivation in one patient. In both cases, drug-induced HLH was primarily considered owing to a high H-score and the absence of other etiology. Patients rapidly improved after treatment discontinuation associated with oral steroids in one patient and did not relapse after subsequent treatment resumption with a concurrent anti-BRAF/anti-MEK combination. In metastatic melanoma HLH may occur either spontaneously in the absence of any treatment as a paraneoplastic condition, related to an intercurrent infection or drug-induced mainly with various immunotherapy or with dabrafenib and trametinib following immunotherapy. However, such observations are scarce and these are the first cases of HLH occurring during first-line treatment with dabrafenib and trametinib in advanced melanoma to our knowledge. Pathomechanisms remain to be elucidated since triggering factors may encompass the treatment itself but also other significant actors including viral reactivation along with the underlying disease. The liability of treatment should be considered in cases of HLH occurring in patients with advanced melanoma successfully treated with a combined targeted therapy. A rechallenge with a concurrent anti-BRAF/anti-MEK can be proposed in this setting.

Published
2020
Full Text
View/download PDF

6. Airborne allergic contact dermatitis caused by artichoke

Author

Agnès Sparsa, Evangéline Clark, Aurélie Du-Thanh, Olivier Dereure, Nadia Raison-Peyron, Quentin Samaran, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and Clinique Mutualiste Catalane

Subjects
0106 biological sciences, Adult, Male, medicine.medical_specialty, MESH: Facial Dermatoses, plant, Dermatology, Biology, 01 natural sciences, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, MESH: Dermatitis, Allergic Contact, Cynara scolymus, sesquiterpene lactones, medicine, Immunology and Allergy, Humans, case report, Allergic contact dermatitis, ComputingMilieux_MISCELLANEOUS, Aged, MESH: Aged, MESH: Humans, airborne, MESH: Adult, Patch Tests, medicine.disease, MESH: Male, MESH: Cynara scolymus, Dermatitis, Allergic Contact, MESH: Patch Tests, Female, allergic contact dermatitis, MESH: Female, Facial Dermatoses, artichoke, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, 010606 plant biology & botany
Abstract

International audience

Published
2020
Full Text
View/download PDF

7. Monoclonal antibodies: also for dermatologists!

Author

Bernard Guillot, Aurélie Du-Thanh, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), and Salvy-Córdoba, Nathalie

Subjects
medicine.medical_specialty, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Therapeutic monoclonal antibodies, medicine.drug_class, omalizumab and lanadelumab, Lanadelumab, Omalizumab, Monoclonal antibody, General Biochemistry, Genetics and Molecular Biology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Psoriasis, dupilumab, medicine, 030212 general & internal medicine, business.industry, General Medicine, Atopic dermatitis, psoriasis, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.disease, Dermatology, Dupilumab, Relative risk, Monoclonal, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, medicine.drug
Abstract

Les anticorps monoclonaux thérapeutiques en dermatologie ont d’abord été utilisés pour la prise en charge du psoriasis, puis, plus récemment, de l’urticaire chronique spontanée et de la dermatite atopique. Trois exemples seront abordés dans cette revue: le dupilumab, l’omalizumab et le lanadélumab. Leur mode d’action spécifique résulte d’une meilleure compréhension des mécanismes inflammatoires de ces maladies chroniques qui partageaient autrefois des traitements topiques ou systémiques plus ou moins ciblés. Leur utilisation onéreuse doit cependant être raisonnée par la mise en perspective de l’épidémiologie, de l’évaluation précise de la sévérité, de l’optimisation des traitements de première ligne, et de la balance bénéfices/risques.

Published
2019
Full Text
View/download PDF

8. Development or Exacerbation of Head and Neck Dermatitis in Patients Treated for Atopic Dermatitis With Dupilumab

Author

Angèle Soria, Delphine Staumont-Sallé, Marie Jachiet, Julien Seneschal, Sébastien Barbarot, Aurélie Du-Thanh, CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de dermatologie Hôpital Saint-André Bordeaux, CHU Bordeaux [Bordeaux], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de dermatologie [Nantes], and Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)

Subjects
medicine.medical_specialty, Exacerbation, business.industry, Nasopharyngitis, Interleukin, Dermatology, Atopic dermatitis, Eosinophil, medicine.disease, Placebo, Dupilumab, 3. Good health, body regions, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Post-hoc analysis, Research Letter, Medicine, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; The efficacy and safety of dupilumab, a humanized monoclonal antibody targeting the α subunit of the interleukin (IL)-4 and IL-13 receptors, has been assessed in adults with moderate-to-severe atopic dermatitis (AD).1,2 Injection site reactions, nasopharyngitis, conjunctivitis, and transient increases in eosinophil counts from baseline were higher in the dupilumab groups than in the placebo groups in pivotal studies.1,2 A recent study by Zhu et al3 reported new regional dermatoses in 17 patients with AD treated with dupilumab, with facial area involvement in 14 cases, whereas Blauvelt et al4 reported an equal improvement of AD with dupilumab on different anatomic regions in a post hoc analysis of data extracted from 4 phase 3 clinical trials.

Published
2019
Full Text
View/download PDF

9. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

Author

A. Schoeffler, Ziad Reguiai, Audrey Lasek, Anne-Sophie Dillies, Jonathan Giovannelli, Nadia Raison-Peyron, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Sarah Faiz, Anne Dompmartin, Laurent Misery, Marie-Aleth Richard, J. Delaunay, Jean-Philippe Lacour, Sandrine Rappelle-Duruy, Jean-Philippe Arnault, Céline Podevin, Anne-Bénédicte Duval-Modeste, Jean-David Bouaziz, Angèle Soria, Amélie Walter-Lepage, Julien Sénéchal, Delphine Staumont-Sallé, François Aubin, Catherine Droitcourt, N. Bellon, Sébastien Barbarot, Stéphane Barete, Florence Tetart, Marie Jachiet, Emmanuel Mahé, Nathalie Beneton, Edouard Begon, Audrey Nosbaum, A. Valois, C. Morice, Service de Dermatologie, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Polyclinique Courlancy (PC), Polyclinique de Courlancy, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Université de Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de dermatologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Service de dermatologie, Hôpital Augustin Morvan-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Dermatologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, Département de dermatologie, CHU Angers, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de Dermatologie et pathologies vasculaires [CH Argenteuil], Centre Hospitalier Victor Dupouy, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Centre Hospitalier René Dubos [Pontoise], CHU La Milétrie, Université de Picardie Jules Verne (UPJV), Service de Dermatologie, Hôpital Joseph Imbert, Centre Hospitalier d'Arles, CHU Pitié-Salpêtrière [AP-HP], Service de dermatologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Le Mans (CH Le Mans), Hôpital d'Instruction des Armées Sainte Anne, Service de Santé des Armées, Neurofibromatosis Clinic, Centre hospitalier universitaire de Nantes (CHU Nantes), Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Normandie Université (NU)-Normandie Université (NU)-Hôpital Charles Nicolle [Rouen], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Augustin Morvan, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Adult, Male, medicine.medical_specialty, Injections, Subcutaneous, [SDV]Life Sciences [q-bio], Kaplan-Meier Estimate, Dermatology, Antibodies, Monoclonal, Humanized, Risk Assessment, Severity of Illness Index, Eczema Area and Severity Index, Drug Administration Schedule, Dermatitis, Atopic, Cohort Studies, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, dupilumab, medicine, conjunctivitis, Humans, SCORAD, Adverse effect, Proportional Hazards Models, Retrospective Studies, Dose-Response Relationship, Drug, medicine.diagnostic_test, business.industry, Antibodies, Monoclonal, Atopic dermatitis, Dermatology Life Quality Index, medicine.disease, adultsatopic dermatitis, Dupilumab, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, Cohort, biotherapy, Female, France, Patient Safety, business, eosinophilia
Abstract

International audience; BackgroundDupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.ObjectiveWe sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.MethodsWe included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.ResultsWe included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10−9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10−9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10−6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.LimitationsNo control group, missing data.ConclusionThis real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

Published
2019
Full Text
View/download PDF

10. Risque de cancers cutanés sous hydrochlorothiazide : revue systématique

Author

Bernard Guillot, O. Becquart, J.-L. Bourrain, Aurélie Du-Thanh, C. Duflos, and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)

Subjects
Drug, medicine.medical_specialty, media_common.quotation_subject, [SDV]Life Sciences [q-bio], Population, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Hydrochlorothiazide, Epidemiology, Internal Medicine, medicine, Basal cell carcinoma, Cancers cutanés, education, media_common, education.field_of_study, business.industry, Melanoma, Gastroenterology, medicine.disease, Dermatology, 3. Good health, Épidémiologie, 030220 oncology & carcinogenesis, Relative risk, Skin cancer, business, medicine.drug
Abstract

International audience; Le risque de cancers cutanés induits par des médicaments photosensibilisants est connu. Le rôle de l’hydrochlorothiazide a été soulevé par plusieurs études épidémiologiques récentes. Une revue systématique des études cas-témoins ou de cohortes prospectives montre qu’il existe un surrisque de carcinomes épidermoïdes dans la majorité des études même si certains facteurs de confusion comme le tabac n’ont pas été pris en compte. Les données sont plus contradictoires pour les carcinomes basocellulaires et les mélanomes. Ces résultats ne remettent pas en cause le rapport bénéfice/risque de cette molécule, mais peuvent inciter à des mesures de prévention renforcées chez les malades pour lesquels une prescription d’hydrochlorothiazide est proposée : identifier les patients à risque de carcinomes cutanés, éviter si possible de prescrire cette molécule chez les patients immunodéprimés ou ayant un carcinome, effectuer un examen cutané régulier chez les malades recevant ce traitement au long cours.

Published
2019
Full Text
View/download PDF

11. Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients

Author

Djaouida Bengoufa, Jean-Luc Schmutz, Thierry Vincent, François Chasset, Jean-David Bouaziz, Anne Cosnes, Aurélie Du-Thanh, Nicolas Molinari, Nadège Cordel, T. Hubiche, Bernard Guillot, Y. Le Corre, Céline Girard, M. Best, Marie Jachiet, Valérie Pallure, F. Manna, M. Dandurand, Olivier Dereure, Didier Bessis, Camille Francès, Dan Lipsker, C. Bulai Livideanu, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Service de dermatologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Institut Montpelliérain Alexander Grothendieck ( IMAG ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Saint Jean de Perpignan, Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université de Strasbourg ( UNISTRA ), CHU Strasbourg, Centre Hospitalier Intercommunal Fréjus - St Raphaël ( CHI Fréjus - St Raphaël ), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre Hospitalier Universitaire d'Angers ( CHU Angers ), PRES Université Nantes Angers Le Mans ( UNAM ), CHU Pointe-à-Pitre/Abymes [Guadeloupe], Centre Hospitalier Régional Universitaire de Nîmes ( CHRU Nîmes ), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ) -Centre Hospitalier Universitaire de Montpellier ( CHU Montpellier ), CHU Toulouse [Toulouse], Service de Dermatologie [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 ( UPD7 ) -CHU Saint Louis [APHP], Université de Montpellier ( UM ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Montpelliérain Alexander Grothendieck (IMAG), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Strasbourg (UNISTRA), Centre Hospitalier Intercommunal Fréjus - St Raphaël (CHI Fréjus - St Raphaël), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Service de dermatologie et allergologie [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Tenon [APHP], and Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP]

Subjects
Adult, Male, medicine.medical_specialty, Interferon-Induced Helicase, IFIH1, Poikiloderma, Dermatology, Hand Dermatoses, Antibodies, Dermatomyositis, Amino Acyl-tRNA Synthetases, 030207 dermatology & venereal diseases, 03 medical and health sciences, Necrosis, Young Adult, 0302 clinical medicine, Calcinosis, Neoplasms, medicine, Humans, Prospective Studies, Prospective cohort study, Aged, Skin, 030203 arthritis & rheumatology, Adenosine Triphosphatases, Aged, 80 and over, business.industry, Interstitial lung disease, Autoantibody, Cancer, Odds ratio, Middle Aged, medicine.disease, 3. Good health, DNA-Binding Proteins, Infectious Diseases, Phenotype, Female, Joint Diseases, business, Lung Diseases, Interstitial, [ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Transcription Factors
Abstract

BACKGROUND: Identification of myositis-specific autoantibodies (MSAs) for dermatomyositis (DM) could allow the characterization of an antibody-associated clinical phenotype. OBJECTIVE: We sought to define the clinical phenotype of DM and the risk of cancer, interstitial lung disease (ILD) and calcinosis based on MSA. METHODS: A 3.5-year multicentre prospective study of adult DM patients was conducted to determine the clinical phenotype associated with MSAs and the presence of cancer, ILD and calcinosis. RESULTS: MSAs were detected in 47.1% of 117 included patients. Patients with antimelanoma differentiation-associated protein-5 antibodies (13.7%) had significantly more palmar violaceous macules/papules [odds ratio (OR) 9.9], mechanic's hands (OR 8), cutaneous necrosis (OR 3.2), articular involvement (OR 15.2) and a higher risk of ILD (OR 25.3). Patients with antitranscriptional intermediary factor-1 antibodies (11.1%), antinuclear matrix protein-2 antibodies (6.8%) and antiaminoacyl-transfer RNA synthetase (5.1%) had, respectively, significantly more poikiloderma (OR 5.9), calcinosis (OR 9.8) and articular involvement (OR 15.2). Cutaneous necrosis was the only clinical manifestation significantly associated with cancer (OR 3.1). CONCLUSION: Recognition of the adult DM phenotype associated with MSAs would allow more accurate appraisal of the risk of cancer, ILD and calcinosis.

Published
2017
Full Text
View/download PDF

12. Macrophage activation syndrome: A new complication of checkpoint inhibitors

Author

Jean-Jacques Grob, N. Malissen, Julie Lacotte, Aurélie Du-Thanh, Caroline Gaudy-Marqueste, Bernard Guillot, Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)

Subjects
0301 basic medicine, Cancer Research, Cell cycle checkpoint, Immune checkpoint inhibitors, Ipilimumab, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Medicine, ComputingMilieux_MISCELLANEOUS, biology, business.industry, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Macrophage activation syndrome, Cancer research, biology.protein, Nivolumab, Antibody, Complication, business, B7-H1 Antigen, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract

International audience

Published
2017
Full Text
View/download PDF

13. Normal PAI-2 level in French FXII-HAE patients

Author

Raphaël Marlu, Laurence Bouillet, Isabelle Boccon-Gibod, Alban Deroux, Aurélie Du-Thanh, David Launay, Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Thérapeutique Recombinante Expérimentale [?-2015] (TIMC-TheREx [?-2015]), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 [2011-2015] (TIMC [2011-2015]), Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-IMAG-Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-IMAG-Institut polytechnique de Grenoble - Grenoble Institute of Technology [2007-2019] (Grenoble INP [2007-2019])-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CREAK Grenoble, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Médecine Interne, CHU Grenoble, and Service de médecine interne [Lille]

Subjects
030201 allergy, medicine.medical_specialty, business.industry, [SDV]Life Sciences [q-bio], Immunology, Angioedemas, Hereditary, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, 030228 respiratory system, Internal medicine, Plasminogen activator inhibitor-2, Plasminogen Activator Inhibitor 2, medicine, Humans, Immunology and Allergy, [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, business, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2017
Full Text
View/download PDF

14. Unusual Facial 'Acne': A Quiz

Author

Olivier Dereure, Luc Durand, Aurélie Du-Thanh, Valérie Costes, Eric Frouin, Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Service de Biopathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)

Subjects
Adult, medicine.medical_specialty, Skin Neoplasms, Biopsy, Physical examination, Dermatology, Asymptomatic, Lymphocytic Infiltrate, Diagnosis, Differential, Predictive Value of Tests, Acne Vulgaris, medicine, Biomarkers, Tumor, Humans, ComputingMilieux_MISCELLANEOUS, Skin, medicine.diagnostic_test, business.industry, Papule, General Medicine, Lymphoma, B-Cell, Marginal Zone, Immunohistochemistry, Chin, medicine.anatomical_structure, Abdomen, Female, medicine.symptom, Differential diagnosis, business, [ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatology, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience; A 31-year-old woman was investigated for multiple, slightly erythematous or flesh-coloured, firm, asymptomatic papu-les, a few mm in diameter, located exclusively on the chin and the lower part of both cheeks (Fig. 1a). These elements had gradually emerged over the 2 previous years and were initially considered and treated unsuccessfully as retentional acne. Physical examination was otherwise unremarkable and the general status of the patient was excellent. Histo-logical examination of a papule displayed a multi-nodular lymphocytic infiltrate of moderate density involving the upper and medium dermis that was well-limited laterally (Fig. 1b). Standard laboratory investigations and routine serologies, including serological diagnosis of Borrelia, were normal or negative. Computed tomography (CT) scan of the chest, abdomen and pelvis was unremarkable. What is your diagnosis? See next page for answer. Fig. 1. Clinical and histological features. (a) Multiple, small-sized papules of the lower part of the face with chronic evolution. (b) multi-nodular dermal infiltrate of moderate density involving the upper and medium dermis with reactive germinal centre-like structures (Haematoxylin-eosin ×5).

Published
2017
Full Text
View/download PDF

15. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema

Author

Pauline Pralong, Aurélie Du-Thanh, Anne Gompel, Alban Deroux, Olivier Fain, Laurence Bouillet, Y. Ollivier, Isabelle Boccon-Gibod, Charles Faisant, Anne Pagnier, Kamel Djenouhat, David Launay, Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service de Médecine Interne [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Grenoble, Service de médecine interne [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gynécologie et Obstétrique [Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Lille Inflammation Research International Center - U 995 (LIRIC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
Adult, Male, Adolescent, Pregnancy Complications, Cardiovascular, Immunology, Asymptomatic, Contraceptives, Oral, Hormonal, C1-inhibitor, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Pregnancy, Icatibant, Humans, Immunology and Allergy, Medicine, Family, Child, C1 inhibitor, Angioedema, biology, business.industry, factor XII, Angioedemas, Hereditary, Original Articles, medicine.disease, hereditary angioedema, 3. Good health, Tranexamic Acid, 030228 respiratory system, chemistry, Mutation, Hereditary angioedema, biology.protein, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, medicine.symptom, bradykinin, business, Complement C1 Inhibitor Protein, Tranexamic acid, Rare disease, medicine.drug
Abstract

Summary Hereditary angioedema (HAE) is a rare disease associated with either a quantitative or qualitative deficiency in C1-inhibitor (C1-INH) or normal C1-INH. HAE with normal C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including 14 German and 15 Spanish families. We have constructed a register of French patients and their characteristics. A national survey was launched through the French National Center of Reference for Angioedema (CREAK) to study the clinical, biological and therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. In most cases they were young women (mean age at diagnosis: 31 years, mean age at first symptom: 21 years, female/male ratio: 76%). Twenty-one per cent of the patients experienced angioedema attacks only during pregnancy or when on oestrogen contraception. Sixty-three per cent had attacks at all times, but they were more severe during these same periods. Male carriers of the mutation were more frequently asymptomatic than females (P = 0·003). C1-INH concentrate and icatibant were both effective for treating attacks. The prophylactic use of tranexamic acid led to a 64% decrease in the number of attacks. This is one of the largest series reported of HAE patients with FXII mutation. The therapeutic management appeared to be identical to that of HAE with C1-INH deficiency.

Published
2016
Full Text
View/download PDF

16. Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis

Author

Olivier Dereure, Bernard Guillot, Céline Girard, Valérie Pallure, Aurélie Du-Thanh, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )

Subjects
medicine.medical_specialty, medicine.medical_treatment, Dacarbazine, Ipilimumab, Dermatology, 03 medical and health sciences, 0302 clinical medicine, Immune system, medicine, Stage (cooking), Colitis, ComputingMilieux_MISCELLANEOUS, 0303 health sciences, Chemotherapy, 030306 microbiology, business.industry, Clostridium difficile, medicine.disease, 3. Good health, Surgery, Diarrhea, 030220 oncology & carcinogenesis, medicine.symptom, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract

We report here the first case of a misleading association of Clostridium difficile infection (CDI) with ipilimumab-related immune diarrhea in a patient with unresectable stage III melanoma.After an unsuccessful first-line chemotherapy with dacarbazine (1000 mg/m2 every three weeks) for a subcutaneous and nodal relapse of a stage IIb melanoma of the right lower limb (Breslow index 3.75 mm, Clark level IV), treated by surgical excision 11 months previously and incomplete adjuvant treatment with alpha [...]

Published
2015
Full Text
View/download PDF

17. Merkel cell polyomavirus: Its putative involvement in a particular subset of cutaneous lymphoma with possibly unfavorable outcome

Author

Vincent Foulongne, Aurélie Du-Thanh, Olivier Dereure, Bernard Guillot, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), and Laboratory of Virology

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Lymphoma, Biopsy, [SDV]Life Sciences [q-bio], Merkel cell polyomavirus, Real-Time Polymerase Chain Reaction, Cutaneous lymphoma, Viral Proteins, Mycosis Fungoides, Virology, medicine, Humans, ComputingMilieux_MISCELLANEOUS, Aged, Skin, Aged, 80 and over, Polyomavirus Infections, Mycosis fungoides, biology, Middle Aged, Viral Load, biology.organism_classification, Folliculotropic Mycosis Fungoides, medicine.disease, Immunohistochemistry, 3. Good health, Carcinoma, Merkel Cell, Tumor Virus Infections, Treatment Outcome, Infectious Diseases, Real-time polymerase chain reaction, DNA, Viral, Immunology, biology.protein, Female, Antibody, Viral load
Abstract

Background A major etiologic hypothesis in primary cutaneous T-cell lymphomas is a defective lymphocyte apoptosis after antigenic activation, which could be induced by various infectious agents. Objective To investigate the presence of the possibly lymphotropic and folliculotropic Merkel cell polyomavirus (MCPyV) DNA and proteins in folliculotropic mycosis fungoides (fMF). Study design Fresh-frozen and fixed skin biopsies were collected in lesional and non-lesional skin from 24 fMF patients, in lesional skin from 22 patients with various T-cell mediated skin benign infiltrates (TSBI) and in normal-appearing skin from 22 healthy individuals (HI). Detection and quantification of MCPyV DNA were carried out using real-time PCR; MCPyV genome integration status was presumed through a previously described differential real-time PCR (MCPyV ΔC-TAg) targeting a constantly conserved sequence versus an integration-induced deleted sequence. The MCPyV proteins expression was assessed by immunohistochemistry using antibodies targeting a tumoral antigen or a capsid protein. Results Although MCPyV DNA was similarly detected in lesional versus non-lesional fMF samples (50% each), in 36.4% HI and 40.9% TSBI; viral load was significantly higher in fMF lesional samples versus HI and TSBI. The integration of the viral genome appeared unlikely. The MCPyV proteins expression was exclusively observed inside skin appendages in 18.2% of the fMF lesional skin samples. Conclusion MCPyV genome detection rate was similar in all skin samples, but MCPyV viral load was significantly higher in fMF lesions versus TSBI and HI, although the viral genome was probably not integrated. Episomal MCPyV DNA may be expressed in skin appendages in fMF.

Published
2014
Full Text
View/download PDF

18. No evidence for viral sequences in mycosis fungoides and Sézary syndrome skin lesions: a high-throughput sequencing approach

Author

Virginie Sauvage, Jean Claude Manuguerra, Olivier Dereure, Kevin Pariente, Marc Eloit, Vincent Foulongne, Aurélie Du Thanh, Justine Cheval, Valérie Caro, Université Montpellier 1 (UM1), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), PathoQuest, Institut Pasteur [Paris], Virologie UMR1161 (VIRO), École nationale vétérinaire d'Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), ProdInra, Migration, Institut Pasteur [Paris] (IP), and École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)

Subjects
Adult, Male, medicine.medical_specialty, Skin Neoplasms, [SDV]Life Sciences [q-bio], Pilot Projects, Dermatology, Biology, Biochemistry, 03 medical and health sciences, Mycosis Fungoides, 0302 clinical medicine, medicine, Humans, Sezary Syndrome, Molecular Biology, Throughput (business), ComputingMilieux_MISCELLANEOUS, 030304 developmental biology, 0303 health sciences, Mycosis fungoides, Base Sequence, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Cell Biology, Middle Aged, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, DNA, Viral, Female, sézary syndrome, Skin lesion
Abstract

International audience

Published
2013
Full Text
View/download PDF

19. Étude descriptive multicentrique des schémas d’optimisation du dupilumab dans la dermatite atopique en France

Author

Strizzolo, Rémi, Thèses d'exercice et mémoires - UFR de Médecine Montpellier-Nîmes, Université de Montpellier (UM), and Aurélie Du Thanh

Subjects
Échappement, Head and neck, Dermatite atopique, Anti-JAK, Optimisation, Dupilumab, Rapprochement, Échec, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Le dupilumab a amélioré la prise en charge de la dermatite atopique (DA) modérée à sévère des patients >12 ans, mais en l’absence de réponse satisfaisante, aucune recommandation n’est disponible. Patients et méthodes : tous les patients DA ayant nécessité une optimisation du dupilumab, après échec ou réponse partielle ou échappement secondaire ou head and neck dermatitis, entre mars 2017 et mars 2021, ont été inclus dans cette étude rétrospective multicentrique. Nous avons recensé les différents schémas d’optimisation du dupilumab, et évalué d’éventuels facteurs de réponse à cette optimisation. Résultats et discussion : 68,7% des 51 patients inclus obtenaient une bonne réponse à l’optimisation, sans différence entre les 4 schémas (ajout de ciclosporine, de méthotrexate, d’itraconazole ou rapprochement des injections de dupilumab). L’optimisation semblait plus efficace lorsqu’il y avait eu un chevauchement initial entre ciclosporine et dupilumab (p=0,03) et si la réponse initiale au dupilumab était partielle. L’échec initial du dupilumab était prédictif d’un échec d’optimisation ultérieure (p=0,05) ; l’échappement secondaire au dupilumab était prédictif d’un échec du rapprochement des injections (p=0,04) ; l’ajout de méthotrexate semblait plus efficace chez les patients avec un DLQI initial bas (p=0,01). Conclusion : notre étude montre l’intérêt de l’optimisation du dupilumab. L’intérêt d’un chevauchement initial avec la ciclosporine reste à évaluer. L’absence de réponse à 3 mois de dupilumab devrait motiver un changement de ligne thérapeutique. Le rapprochement des injections semblait bénéfique pour les patients avec une réponse partielle initiale, sans différence selon le poids. L’ajout de méthotrexate serait à réserver aux DA d’intensité modérées initialement.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results